MultiCell Technologies Inc. Obtains Patent Protection In Several European Countries For Treatment Of Autoimmune Diseases

SAN DIEGO--(BUSINESS WIRE)--MultiCell Technologies, Inc. (OTCBB:MCET), developing first-in-class drugs based on advanced immune system modulation and other proprietary technologies, today announced it has obtained patent protection for their latest issued European patent in several countries, including France, Germany, Switzerland, U.K., Ireland, Belgium, Luxembourg and Monaco. This patent covers next generation technology from MCET, targeting multibillion-dollar medical marketplace segments, including a range of serious autoimmune disorders such as type-1 diabetes and multiple sclerosis.